Question
Give a brief account of toxicity studies in tabular form.
Answer :
Word Count : 1049
In the field of Drugs Regulatory Affairs, toxicity studies are essential components of preclinical drug development, providing critical information about the safety profile of a new drug candidate. These studies are designed to evaluate the potential harmful effects of drugs on biological systems and guide the establishment of safe dosage ranges for humans. Toxicity studies are broadly categorized based on the duration of exposure, the type of toxic effects investigated, and the biological systems involved. They are governed by international regulatory guidelines such as ICH (International Council for Harmonisation) M3(R2), OECD (Organisation for Economic Co-operation and Development) guidelines, and country-specific frameworks like the US FDA and CDSCO (Central Drugs Standard Control Organization) regulations in India. Acute toxicity studies are the first step in evaluating a drug's safety. These studies involve the administration of a single dose or multiple doses within 24 hours to animals, typically rodents, to determine the immediate toxic effects and the median lethal dose (LD50). The primary goal is to observe the onset of toxicity, target organ effects, clinical signs, and mortality. Acute toxicity data help in selecting starting doses for sub-acute and chronic studies and in identifying potential emergency toxic reactions. Sub-acute or repeated dose toxicity studies involve the administration of the drug over a period ranging from 14 to 28 days. These studies are performed in at least two species (one rodent and one non-rodent) and are designed to evaluate cumulative toxicity, dose-response relationships, and reversibility of toxic effects. Parameters such as body weight, food consumption, hematology, clinical biochemistry, organ weights, and histopathology are monitored to identify _______ __________ ____ ______ _____ ______ ___ ____ _________ _______ _______.
_____ ______ ________ ___ ______ _________ ____.
______ ____ ____ ____ ___.
___ ___ ________ _____ ________ _________ ___ __________ ____ ________.
___ _________ __________ _______ ________ ________ _____ __________ ______ ___ __________ ______.
____ __________ _____ __________ ________ __________ ________.
________ ___ _________ ______ ____ ______ ________ _____ ___.
_________ __________ _________ ___ _______ ______ ___ ___ _______.
___ ________ ____ _________ _____ _____ ____ ___.
__________ ___ ___ ______ ________ ______.
_________ ________ ________ ________ ________ ____ _____ ____ ___ _____ ___ _____.
_____ ____ __________ ____ ____ ___ __________ ___ _____ _________ _______ _________.
_______ ______ _______ ______ ___ ______ ______ _______.
_____ _______ ______ ____ __________ ___ ______ ___.
________ ________ ________ _______ ___ _____.
_________ ____ ______ ______ _____ __________ ____.
________ ______ _____ ___ __________ _____ ___ _______ __________.
____ ______ _______ ____ _____ ________ ______.
_______ ________ ____ ___ __________ _________ ______ ____ ___ ___ ___ ____.
_________ _______ ____ ________ _____ _______ __________ _______ ________.
___ _________ _____ ____ ____ ____ ___.
_____ _____ _________ _______ __________ ___ __________ ________.
________ __________ ________ _____ ____ ___ ______ ________.
______ __________ ______ ________ ________ ____ _________ _____ ______.
_______ ________ ____ _________ _________.
____ __________ ___ _________ ______ __________ ________.
_________ ___ __________ _______ ________ ________ ___ ______ ___ _______ ____.
______ _______ __________ ___ ___ _______ ____ ________ _____ _____ ____.
________ _________ __________ _____ _____ _______ ___.
__________ _________ __________ ___ ___ _________.
_____ ___ ________ ___ ____ ________ ________ __________ ____ _____ ____ ________.
____ _______ _____ ___ ________ __________.
____ __________ ____ _______ ______ ____ __________ ____ __________ _______ ___ ________.
___ ___ ___ ________ _____ ________ _________ _____.
_________ ________ _____ __________ __________ _________ ___ ____.
________ _____ _________ _________ __________ __________ ___.
______ ___ __________ _______ __________ _______.
__________ ______ ____ _____ __________ ________ ____ ________ ____ ______.
__________ ___ _____ ________ _____ ________ ____ ____ _________ ___ ______.
_________ _____ __________ ____ ___ _________ _________ ____ _________ _______ ______ __________.
_________ __________ ____ ______ _____ ______ _________ ________ ____ ______.
______ ____ _______ __________ ____ _____ _______ _______ __________.
_______ ___ ___ _______ ________ _______ _________ ________ _____ _____ _______ ____.
______ ____ _________ _________ __________ __________.
_______ ___ __________ __________ ______ ___ ______ ___ ________ ____ ___ ________.
________ _______ _________ ______ _________ ________.
______ ______ ________ ____ _______ __________ _____ ____ ______.
_______ ____ __________ ___ ________ _______ _____ ____ __________ ________ ______.
____ _________ _________ _________ _______.
__________ __________ ______ _________ ___.
_________ ______ _________ _______ _________ ______ ___.
____ _________ __________ ____ _________ ________ ________.
_________ __________ ____ __________ ___ ____ __________ __________ ____ _____ ______ ________.
__________ ________ _________ ______ ________ _____ _________.
_______ _______ _____ __________ _______ _________ _____ _________ ___ _________.
__________ ________ ______ _____ _____.
________ _______ ____ ___ ________ ___ _________ ____ ______.
_________ _______ ________ __________ _________ ___ ___ _______ _______ _________ __________.
_______ _______ _____ ___ ________ _________ ______.
__________ ___ _______ _______ _______ ____ __________ _______.
__________ __________ ____ _______ ________ _______.
___ _______ ____ ____ ____ ____ ____ ___ ________ ___.
______ _________ _________ ______ ___ _________ ________ _______ __________ _____ _____.
__________ ______ _________ ___ ____.
________ ___ ___ _____ ___ ____ _______ _____ __________ ________.
_________ ______ ______ _____ ___.
__________ _________ ______ __________ ___ ___ ___ _________ __________.
__________ ________ ______ _______ _______.
__________ ______ _______ _________ ____ _____ ____ ______ ___.
_______ __________ ___ ____ _________ __________ _____ ______ ________.
________ _________ ______ ______ ______ ______ ________ _________ __________.
______ ________ _____ ______ _________ _____ _________ __________.
_____ __________ ______ ______ _________ ___ __________ ______ ______ ___.
________ ___ _____ ________ _____ __________ _____ ______ ___.
______ ________ _________ ___ ____ ____.
__________ _________ ______ __________ __________ _________ ___ _____ ___.
________ ___ ______ _________ ______ ____ _______ ______ _____.
__________ ___ ___ _______ ____.
___ _____ ___ _________ _______ _________ _________ _________ _____.
__________ ______ __________ _________ _________ _________ ____ _________ ___ _________.
____ ________ ____ ________ _____ _______ ________ ___ ____ ______.
____ ________ ________ ___ ________ ___ ____ __________ ___ _________ ___.
_____ __________ __________ ______ _________ ______ ___.
_______ ___ ________ ____ _______ ____ _______ _______ ______ _____ ________.
________ ________ ___ _____ ________ ________ _________ __________ ________ ______ ________ _____.
_____ _______ _____ ___ _____ ______ _____ ____ ___ _____ _______ _____.
________ ____ _____ __________ _____ _____ _____ _____ ___ ______ ____ ________.
________ __________ ___ _______ ______ ___ ________ __________ ___ _________ ____.
____ ___ ____ ______ ________ ____ _________ _________ __________ __________ _____ ________.
_____ ___ __________ ____ _____ ______ _______ ____ ________ ___ _________.
______ ______.
Get Full Answer on WhatsApp
In the field of Drugs Regulatory Affairs, toxicity studies are essential components of preclinical drug development, providing critical information about the safety profile of a new drug candidate. These studies are designed to evaluate the potential harmful effects of drugs on biological systems and guide the establishment of safe dosage ranges for humans. Toxicity studies are broadly categorized based on the duration of exposure, the type of toxic effects investigated, and the biological systems involved. They are governed by international regulatory guidelines such as ICH (International Council for Harmonisation) M3(R2), OECD (Organisation for Economic Co-operation and Development) guidelines, and country-specific frameworks like the US FDA and CDSCO (Central Drugs Standard Control Organization) regulations in India. Acute toxicity studies are the first step in evaluating a drug's safety. These studies involve the administration of a single dose or multiple doses within 24 hours to animals, typically rodents, to determine the immediate toxic effects and the median lethal dose (LD50). The primary goal is to observe the onset of toxicity, target organ effects, clinical signs, and mortality. Acute toxicity data help in selecting starting doses for sub-acute and chronic studies and in identifying potential emergency toxic reactions. Sub-acute or repeated dose toxicity studies involve the administration of the drug over a period ranging from 14 to 28 days. These studies are performed in at least two species (one rodent and one non-rodent) and are designed to evaluate cumulative toxicity, dose-response relationships, and reversibility of toxic effects. Parameters such as body weight, food consumption, hematology, clinical biochemistry, organ weights, and histopathology are monitored to identify _______ __________ ____ ______ _____ ______ ___ ____ _________ _______ _______.
_____ ______ ________ ___ ______ _________ ____.
______ ____ ____ ____ ___.
___ ___ ________ _____ ________ _________ ___ __________ ____ ________.
___ _________ __________ _______ ________ ________ _____ __________ ______ ___ __________ ______.
____ __________ _____ __________ ________ __________ ________.
________ ___ _________ ______ ____ ______ ________ _____ ___.
_________ __________ _________ ___ _______ ______ ___ ___ _______.
___ ________ ____ _________ _____ _____ ____ ___.
__________ ___ ___ ______ ________ ______.
_________ ________ ________ ________ ________ ____ _____ ____ ___ _____ ___ _____.
_____ ____ __________ ____ ____ ___ __________ ___ _____ _________ _______ _________.
_______ ______ _______ ______ ___ ______ ______ _______.
_____ _______ ______ ____ __________ ___ ______ ___.
________ ________ ________ _______ ___ _____.
_________ ____ ______ ______ _____ __________ ____.
________ ______ _____ ___ __________ _____ ___ _______ __________.
____ ______ _______ ____ _____ ________ ______.
_______ ________ ____ ___ __________ _________ ______ ____ ___ ___ ___ ____.
_________ _______ ____ ________ _____ _______ __________ _______ ________.
___ _________ _____ ____ ____ ____ ___.
_____ _____ _________ _______ __________ ___ __________ ________.
________ __________ ________ _____ ____ ___ ______ ________.
______ __________ ______ ________ ________ ____ _________ _____ ______.
_______ ________ ____ _________ _________.
____ __________ ___ _________ ______ __________ ________.
_________ ___ __________ _______ ________ ________ ___ ______ ___ _______ ____.
______ _______ __________ ___ ___ _______ ____ ________ _____ _____ ____.
________ _________ __________ _____ _____ _______ ___.
__________ _________ __________ ___ ___ _________.
_____ ___ ________ ___ ____ ________ ________ __________ ____ _____ ____ ________.
____ _______ _____ ___ ________ __________.
____ __________ ____ _______ ______ ____ __________ ____ __________ _______ ___ ________.
___ ___ ___ ________ _____ ________ _________ _____.
_________ ________ _____ __________ __________ _________ ___ ____.
________ _____ _________ _________ __________ __________ ___.
______ ___ __________ _______ __________ _______.
__________ ______ ____ _____ __________ ________ ____ ________ ____ ______.
__________ ___ _____ ________ _____ ________ ____ ____ _________ ___ ______.
_________ _____ __________ ____ ___ _________ _________ ____ _________ _______ ______ __________.
_________ __________ ____ ______ _____ ______ _________ ________ ____ ______.
______ ____ _______ __________ ____ _____ _______ _______ __________.
_______ ___ ___ _______ ________ _______ _________ ________ _____ _____ _______ ____.
______ ____ _________ _________ __________ __________.
_______ ___ __________ __________ ______ ___ ______ ___ ________ ____ ___ ________.
________ _______ _________ ______ _________ ________.
______ ______ ________ ____ _______ __________ _____ ____ ______.
_______ ____ __________ ___ ________ _______ _____ ____ __________ ________ ______.
____ _________ _________ _________ _______.
__________ __________ ______ _________ ___.
_________ ______ _________ _______ _________ ______ ___.
____ _________ __________ ____ _________ ________ ________.
_________ __________ ____ __________ ___ ____ __________ __________ ____ _____ ______ ________.
__________ ________ _________ ______ ________ _____ _________.
_______ _______ _____ __________ _______ _________ _____ _________ ___ _________.
__________ ________ ______ _____ _____.
________ _______ ____ ___ ________ ___ _________ ____ ______.
_________ _______ ________ __________ _________ ___ ___ _______ _______ _________ __________.
_______ _______ _____ ___ ________ _________ ______.
__________ ___ _______ _______ _______ ____ __________ _______.
__________ __________ ____ _______ ________ _______.
___ _______ ____ ____ ____ ____ ____ ___ ________ ___.
______ _________ _________ ______ ___ _________ ________ _______ __________ _____ _____.
__________ ______ _________ ___ ____.
________ ___ ___ _____ ___ ____ _______ _____ __________ ________.
_________ ______ ______ _____ ___.
__________ _________ ______ __________ ___ ___ ___ _________ __________.
__________ ________ ______ _______ _______.
__________ ______ _______ _________ ____ _____ ____ ______ ___.
_______ __________ ___ ____ _________ __________ _____ ______ ________.
________ _________ ______ ______ ______ ______ ________ _________ __________.
______ ________ _____ ______ _________ _____ _________ __________.
_____ __________ ______ ______ _________ ___ __________ ______ ______ ___.
________ ___ _____ ________ _____ __________ _____ ______ ___.
______ ________ _________ ___ ____ ____.
__________ _________ ______ __________ __________ _________ ___ _____ ___.
________ ___ ______ _________ ______ ____ _______ ______ _____.
__________ ___ ___ _______ ____.
___ _____ ___ _________ _______ _________ _________ _________ _____.
__________ ______ __________ _________ _________ _________ ____ _________ ___ _________.
____ ________ ____ ________ _____ _______ ________ ___ ____ ______.
____ ________ ________ ___ ________ ___ ____ __________ ___ _________ ___.
_____ __________ __________ ______ _________ ______ ___.
_______ ___ ________ ____ _______ ____ _______ _______ ______ _____ ________.
________ ________ ___ _____ ________ ________ _________ __________ ________ ______ ________ _____.
_____ _______ _____ ___ _____ ______ _____ ____ ___ _____ _______ _____.
________ ____ _____ __________ _____ _____ _____ _____ ___ ______ ____ ________.
________ __________ ___ _______ ______ ___ ________ __________ ___ _________ ____.
____ ___ ____ ______ ________ ____ _________ _________ __________ __________ _____ ________.
_____ ___ __________ ____ _____ ______ _______ ____ ________ ___ _________.
______ ______.
Get Full Answer on WhatsApp
IGNOU NEWS
Assignment Submission Last Date Extended Till 30 June 2026 Click Here★★★IGNOU June 2026 TEE Date Sheet Released Click Here★★★